|
1
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Ziger A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019.
2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dillman RO: Infusion reactions associated
with the therapeutic use of monoclonal antibodies in the treatment
of malignancy. Cancer Metastasis Rev. 18:465–471. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kabbinavar FF, Schulz J, McCleod M, Patel
T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF:
Addition of bevacizumab to bolus fluorouracil and leucovorin in
first-line metastatic colorectal cancer: Results of a randomized
phase II trial. J Clin Oncol. 23:3697–3705. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
National Comprehensive Cancer Network
(NCCN): NCCN Guidelines Central Nervous System: Cancers. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
Accessed July 13, 2022.
|
|
8
|
National Comprehensive Cancer Network
(NCCN): NCCN Guidelines Central Nervous System: Cancers. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Accessed July 13, 2022.
|
|
9
|
Shah SR, Gressett Ussery SM, Dowell JE,
Marley E, Liticker J, Arriaga Y and Verma U: Shorter bevacizumab
infusions do not increase the incidence of proteinuria and
hypertension. Ann Oncol. 24:960–965. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Terazawa T, Nishitani H, Kato K, Hashimoto
H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y and
Shimada Y: The feasibility of a short bevacizumab infusion in
patients with metastatic colorectal cancer. Anticancer Res.
34:1053–1056. 2014.PubMed/NCBI
|
|
11
|
Makris G, Kantzioura A, Beredima M,
Karampola M and Emmanouilides C: Feasibility of rapid infusion of
the initial dose of bevacizumab in patients with cancer. J BUON.
20:923–927. 2015.PubMed/NCBI
|
|
12
|
Yanmaz MT, Guner SI, Satılmıs B, Akyol H
and Aydın MA: Thirty-minutes infusion rate is safe enough for
bevacizumab; no need for initial prolong infusion. Med Oncol.
31(276)2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Reidy DL, Chung KY, Timoney JP, Park VJ,
Hollywood E, Sklarin NT, Muller RJ and Saltz LB: Bevacizumab 5
mg/kg can be infused safely over 10 minutes. J Clin Oncol.
25:2691–2695. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mir O, Alexandre J, Coriat R, Ropert S,
Boudou-Rouquette P, Bui T, Chapron J, Durand JP, Dusser D and
Goldwasser F: Safety of bevacizumab 7.5 mg/kg infusion over 10
minutes in NSCLC patients. Invest New Drugs. 30:1756–1760.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
National Comprehensive Cancer Network
(NCCN): NCCN Guidelines Central Nervous System: Cancers. https://www.nccn.org/professionals/physicio_gls/pdf/colon.pdf.
Accessed July 13, 2022.
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
National Cancer Institute. Common
Terminology Criteria for Adverse Events (CTCAE) v4.0 https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fctep.cancer.gov%2Fprotocoldevelopment%2Felectronic_applications%2Fdocs%2FCTCAE_4.03.xlsx&wdOrigin=BROWSELINK.
|
|
18
|
Yamazaki K, Nagase M, Tamagawa H, Ueda S,
Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T,
et al: Randomized phase III study of bevacizumab plus FOLFIRI and
bevacizumab plus mFOLFOX6 as first-line treatment for patients with
metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27:1539–1546.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
McDermott DF, Huseni MA, Atkins MB, Motzer
RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et
al: Clinical activity and molecular correlates of response to
atezolizumab alone or in combination with bevacizumab versus
sunitinib in renal cell carcinoma. Nat Med. 24:749–757.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Antoniotti C, Borelli B, Rossini D,
Pietrantonio F, Morano F, Salvatore L, Lonardi S, Marmorino F,
Tamberi S, Corallo S, et al: AtezoTRIBE: A randomised phase II
study of FOLFOXIRI plus bevacizumab alone or in combination with
atezolizumab as initial therapy for patients with unresectable
metastatic colorectal cancer. BMC Cancer. 20(683)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Damato A, Bergamo F, Antonuzzo L, Nasti G,
Iachetta F, Romagnani A, Gervasi E, Larocca M and Pinto C:
FOLFOXIRI/Bevacizumab plus nivolumab as first-line treatment in
metastatic colorectal cancer RAS/BRAF mutated: Safety run-in of
phase II NIVACOR trial. Front Oncol. 11(766500)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mettu NB, Ou FS, Zemla TJ, Halfdanarson
TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB,
et al: Assessment of capecitabine and bevacizumab with or without
atezolizumab for the treatment of refractory metastatic colorectal
cancer: A randomized clinical trial. JAMA Netw Open.
5(e2149040)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tang PA, Bentzen SM, Chen EX and Siu LL:
Surrogate end points for median overall survival in metastatic
colorectal cancer: Literature-based analysis from 39 randomized
controlled trials of first-line chemotherapy. J Clin Oncol.
25:4562–4568. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Aljehani MA, Morgan JW, Guthrie LA, Jabo
B, Ramadan M, Bahjri K, Lum SS, Selleck M, Reeves ME, Garberoglio C
and Senthil M: Association of primary tumor site with mortality in
patients receiving bevacizumab and cetuximab for metastatic
colorectal cancer. JAMA Surg. 153:60–67. 2018.PubMed/NCBI View Article : Google Scholar
|
